What question did this study set out to answer?

The study aims to assess the safety and effectiveness of intradermal collagen injections for treating genitourinary syndrome of menopause (GSM).

February 12, 2026Journal of Clinical Medicine0 citationsOpen Access

Vulvovaginal Collagen Injection as a Regenerative Strategy in Genitourinary Syndrome of Menopause: Results of a Pilot Study

APAna Isabel Borobia PérezHospital Universitario La Paz JEJavier Jesús Estévez EspejoHospital Universitario La Paz MJMaría Jiménez-GonzálezHospital Universitario La Paz

Key Points

The study aims to assess the safety and effectiveness of intradermal collagen injections for treating genitourinary syndrome of menopause (GSM).
Conducted a retrospective study with 20 women diagnosed with GSM.
Administered multipoint intradermal collagen injections in the vulvovaginal region.
Evaluated clinical outcomes using various scales such as VAS, VHI, vHI, and VSQ.
VAS pain scores dropped significantly from 5.9 to 0.8 after treatment (p < 0.001).
Pain during intercourse decreased from 8.7 to 2.0 (p < 0.001).
100% of patients reported improvement in at least one symptom domain in the VSQ.
80% of participants felt 'much better' according to the CGI scale.

Abstract

Background/Objectives: Genitourinary syndrome of menopause (GSM) is a common and under-diagnosed condition that significantly affects the quality of life of post-menopausal women. Conventional treatments, especially those based on estrogens, have limitations, which has prompted the search for alternative therapies in the field of regenerative medicine. In this context, intradermal injectable collagen, with regenerative and analgesic properties, could represent an innovative option. This study aims to evaluate the efficacy and safety of multipoint intradermal injections of collagen (MD-Tissue) in the treatment of GSM refractory to conventional first-line therapy. Methods: A retrospective study was conducted in 20 patients diagnosed with GSM. Intradermal injections of collagen were administered in the vulvovaginal region. Clinical outcome was assessed using the Visual Analog Scale (VAS) for baseline pain and dyspareunia, the Vaginal Health Index (VHI), the Vulvar Health Index (vHI), the Vulvovaginal Symptoms Questionnaire (VSQ) and the Clinical Global Impression scale (CGI). Results: Three months after end of injections, baseline pain measured using the VAS was significantly reduced from a mean of 5.9 to 0.8 (p < 0.001), and pain during intercourse decreased from 8.7 to 2.0 (p < 0.001). Significant improvements were also observed in the tissue parameters of VHI and vHI. In the VSQ, 100% of patients reported improvement in at least one domain, including itching, dryness, burning, and social and sexual impact. According to the CGI scale, 80% reported feeling ‘much better’ and 20% ‘moderately better’. No relevant adverse effects were reported. Conclusions: Intradermal vulvovaginal collagen injections appear to be a safe and potentially effective intervention in improving pain and other symptoms of GSM, within the regenerative medicine approach. These preliminary results justify prospective studies, with larger sample sizes and long-term follow-up, to confirm and consolidate clinical utility.

AI से पूछें

Bookmark

View Full Paper